Keywords
COVID-19
Pandemics
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Describe the profile of the pediatric population with Down syndrome (DS) hospitalized with severe acute respiratory syndrome (SARS) due to COVID-19 in the first 3 years of the pandemic in Brazil. Methods: Study of epidemiological surveillance with data from the Influenza and other respiratory virus surveillance network (SIVEP-GRIPE) between February 2020 and December 2022. The variables included were demographic data, comorbidities, symptoms, length of hospitalization, admission to the Intensive Care Unit (ICU), days of ICU stay, use of ventilatory support, and case outcomes. Results: The records of 1,570,446 cases hospitalized for SARS, with a positive test for COVID-19 and known outcomes were evaluated. Of these, 658 patients (0.04%) were pediatric patients with DS. Over the 3 years, most of the individuals evaluated were white and lived in the southeast region, with no predominance between genders. There was no variation over the years regarding the comorbidities presented by the patients and the symptoms at admission. Conclusion: Over the first 3 years of the pandemic, the clinical picture presented by patients hospitalized for SARS-CoV-2 SARS was similar.
References
BELLINO S, et al. COVID-19 disease severity risk factors for pediatric patients in Italy. Pediatrics, 2020; 146(4): e2020009399.
BIALEK S, et al. Coronavirus disease 2019 in children—United States, February 12–April 2, 2020. MMWR Morb Mortal Wkly Rep, 2020; 69(14): 422–426.
BOSCHIERO MN, et al. Clinical characteristics and comorbidities of COVID-19 in unvaccinated patients with Down syndrome: first year report in Brazil. Human Genetics, 2022; 141(12): 1887–1904.
BRASIL. Ministério da Saúde. Saibacomo é feita a definição de casossuspeitos de COVID-19 no Brasil. Portal Gov.br, 2021.
BRASIL. Ministério da Saúde. Ministério da Saúdeincorporavacina COVID-19 para crianças de 6 meses a menores de 5 anos no SUS. Portal Gov.br, 2022.
CASTAGNOLI R, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatrics, 2020; 174(9): 882–889.
CHAUHAN K, et.al. COVID-19 infection and Down syndrome—challenges and future directions for care in children. Neurological Sciences, 2022; 43(9): 5181–5182.
DONG Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics, 2020; 145(6): e20200702.
EMAMI A, et al. COVID-19 in patients with Down syndrome. Neurological Sciences, 2021; 42(5): 1649–1652.
EMES D, et al. COVID-19 in children with Down syndrome: Data from the Trisomy 21 Research Society survey. Journal of Clinical Medicine, 2021; 10(21): 5125.
FERREIRA-VASQUES AT e LAMÔNICA DAC. Motor, linguistic, personal and social aspects of children with Down syndrome. Journal of Applied Oral Science, 2015; 23(4): 424–430.
GENSOUS N, et al. Down syndrome, accelerated aging and immunosenescence. Seminars in Immunopathology, 2020; 42(5): 635–645.
GOVERNO DO BRASIL. Dia Mundial da Síndrome de Down celebraaimportância da inclusão. Portal Gov.br, 2022.
HÜLS A, et al. Medical vulnerability of individuals with Down syndrome to severe COVID-19: Data from the Trisomy 21 Research Society and the UK ISARIC4C survey. EClinicalMedicine, 2021; 33: 100769.
HÜLS A, et al. COVID-19 vaccination of individuals with Down syndrome—data from the Trisomy 21 Research Society survey on safety, efficacy, and factors associated with the decision to be vaccinated. Vaccines, 2022; 10(4): 572.
KOELLE K, et al. The changing epidemiology of SARS-CoV-2. Science, 2022; 375(6585): 1116–1121.
LEUNG C, et al. Risk for severe illness and death among pediatric patients with Down syndrome hospitalized for COVID-19, Brazil. Emerging Infectious Diseases, 2023; 29(1): 26–35.
LU X, et al. SARS-CoV-2 infection in children. New England Journal of Medicine, 2020; 382(17): 1663–1665.
MEHTA OP, et al. Coronavirus disease (COVID-19): comprehensive review of clinical presentation. Frontiers in Public Health, 2021; 8: 582932.
PARRI N, et al. Children with COVID-19 in pediatric emergency departments in Italy. New England Journal of Medicine, 2020; 383(2): 187–190.
HOSPITAL DAS CLÍNICAS DA FMUSP. Primeiravacinação do públicoinfantil no Brasil contra COVID-19 começou no HCFMUSP. Faculdade de Medicina da USP, 2022.
SANTORO SL, et al. Pneumonia and respiratory infections in Down syndrome: a scoping review of the literature. American Journal of Medical Genetics Part A, 2021; 185(1): 286–299.
SHEKERDEMIAN LS, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatrics, 2020; 174(9): 868–873.
SOUSA BLA, et al. Non-communicable diseases, sociodemographic vulnerability and the risk of mortality in hospitalized children and adolescents with COVID-19 in Brazil: a cross-sectional observational study. BMJ Open, 2021; 11(9): e050724.
GOVERNO DO ESTADO DE SÃO PAULO. SP começa a vacinaradolescentes de 12 a 17 anos a partir de 23 de agosto. Portal do Governo do Estado de São Paulo, 2021.
TAGARRO A, et al. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. JAMA Pediatrics, 2021; 175(3): 316–317.
WITKOWSKI JM, et al. Immunosenescence and COVID-19. Mechanisms of Ageing and Development, 2022; 204: 111672.
WU Z, MCGOOGAN JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020; 323(13): 1239–1242.